Prognostic significance of the preoperative systemic immune-inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy

Sheng-Ping Hung1 | Pei-Rung Chen2 | Tsung-Ying Ho3 | Kai-Ping Chang4 | Wen-Chi Chou5 | Ching-Hsin Lee1 | Yao-Yu Wu1 | Po-Jui Chen1 | Chia-Hsin Lin1 | Yung-Chih Chou1 | Kang-Hsing Fan6 | Chien-Yu Lin1 | Bing-Shen Huang1,7 | Joseph Tung-Chieh Chang1 | Chun-Chieh Wang1 | Ngan-Ming Tsang1

1Department of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
2Department of Anesthesiology, Mackay Memorial Hospital, Taipei, Taiwan
3Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
4Department of Otolaryngology-Head Neck Surgery, Linkou Chang Gung Memorial Hospital, Chang Gung University at Lin-Kou, Taoyuan, Taiwan
5Department of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou and Chang Gung University, College of Medicine, Taoyuan, Taiwan
6Department of Radiation Oncology, New Taipei Municipal Tucheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
7Department of Radiation Oncology, Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Correspondence
Ngan-Ming Tsang, Department of Radiation Oncology, Proton and Radiation Therapy Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. No. 5, Fuxing St., Guishan Dist., Taoyuan City 33305, Taiwan, R.O.C. Email: tsangnmrt123@gmail.com

Abstract

Objectives: To investigate the prognostic value of the preoperative systemic immune-inflammation index (SII) in patients with oral cavity squamous cell carcinoma (OC-SCC) treated with curative surgery followed by adjuvant radiotherapy (RT) or chemoradiotherapy (CCRT).

Materials and Methods: We retrospectively reviewed the clinical records of patients with OC-SCC who received surgery and postoperative adjuvant RT/CCRT between January 2005 and December 2012. Blood samples were drawn in the 2 weeks preceding surgery. SII was calculated by multiplying the absolute neutrophil and platelet counts, and then, divided by the absolute lymphocyte count, and its optimal cutoff value was identified using the Youden’s index. The study endpoints included overall survival (OS), local control (LC), regional control (RC), and distant control (DC).

Results: The study sample consisted of 993 patients (58.8% of them treated with CCRT). The optimal cutoff value for SII was 810.6. A total of 347 (34.9%) study participants had high preoperative SII values. After allowance for potential confounders in multivariable analysis, high SII values were independently associated with less favorable DC (adjusted hazard ratio [HR] = 1.683, \( p = 0.001 \)) and OS (adjusted HR = 1.466, \( p < 0.001 \)). No independent association between SII and LC/RC was observed.

Conclusion: Increased SII values predict poor DC and OS in patients with OC-SCC treated with curative resection and adjuvant RT/CCRT. Owing to the higher risk of systemic failure in this patient group, a thorough follow-up surveillance schedule may be advisable pending independent confirmation of our data.

Keywords
oral cavity squamous cell carcinoma, prognosis, radiotherapy/chemoradiotherapy, risk factors, systemic immune-inflammation index
1 | INTRODUCTION

Growing evidence indicates that inflammation is involved in cancer initiation, progression, and metastasis. Some readily available parameters originated from routine complete blood count (CBC)—including neutrophils, lymphocytes, monocytes, platelets, and different blood cell ratios—have been found to predict disease recurrence, progression, and survival in patients with head and neck malignancies.

The systemic immune-inflammation index (SII)—which is calculated from CBC by multiplying the absolute neutrophil and platelet counts, and then, divided by the absolute lymphocyte count—has prognostic value in several solid tumors. Notably, a previous study found that high SII values predict less favorable overall survival (OS) and disease-free survival (DFS) in patients with oral cavity squamous cell carcinoma (OC-SCC) after curative resection. However, postoperative radiotherapy (RT)—the treatment modality recommended by the National Comprehensive Cancer Network (NCCN) guidelines—was given to less than one-third of their study patients with nodal metastases. Concurrent chemoradiotherapy (CCRT) is also recommended for patients with OC-SCC who carry major pathological risk factors—including positive margins and extranodal extension (ENE).

While both RT and CCRT are known to improve locoregional control, the prognostic value of SII in patients with OC-SCC who had been treated with curative resection followed by adjuvant RT/CCRT remains unclear. The aim of this retrospective study was twofold, that is, (1) to address this issue using different endpoints related to local, regional, and distant control, and (2) to analyze the predictive ability of SII while taking into account the confounding effect of various clinical and pathological risk factors.

2 | MATERIALS AND METHODS

2.1 | Study patients

This single-center study was conducted in a tertiary medical center between 1 January 2005 and 31 December 2012. All of the patients were followed up from the first day of RT until death or censored on the date of last follow-up (31 July 2019). We identified a total of 1178 patients with nonmetastatic OC-SCC who met the following inclusion criteria: (1) treatment with radical surgery and adjuvant RT/CCRT and (2) no history of secondary cancer diagnosed in the 3 years preceding or following treatment for OC-SCC. Exclusion criteria were as follows: (1) incomplete pathology report (margin data were required for inclusion; n = 162), (2) unconventional RT dose fraction (n = 10), (3) diagnosis of major or minor salivary gland tumors different from SCC, (n = 8), (4) synchronous tonsil cancer without curative resection (n = 2), and (5) history of an active infectious or inflammatory disorder in the 30 days preceding surgery for OC-SCC (n = 3). Figure 1 depicts the flow of patients through the study. The protocol complied with the tenets of the Helsinki declaration, and ethics approval was granted by the local Institutional Review Board (approval number: 202000259B0). Owing to the retrospective nature of the study, the need for informed consent was waived.

2.2 | Treatment approach and follow-up schedule

Patients treated with radical surgery were offered adjuvant therapy (CCRT or RT) according to the presence of specific

---

**FIGURE 1** Flow of patients through the study. Abbreviations: OC, oral cavity; OP, operation; RT, radiotherapy; CCRT, chemoradiotherapy; SCC, squamous cell carcinoma

| Inclusion Criteria: |
|--------------------|
| 1. Patients with OC cancer |
| 2. Received OP and adjuvant RT/CCRT |
| 3. No metastasis at presentation (MD) |
| 4. No preceding/secondary cancer |

(n = 1178)

Data Obtained

(n = 993)

| Lower SII |
|-----------|
| n = 646   |

| High SII |
|----------|
| n = 347  |

Exclusion:

- Incomplete Pathology report, n = 162
- Not conventional RT fraction size, n = 10
- Synchronous head and neck cancer without resection, n = 2
- Not SCC, n = 8
- Active infection/ inflammation in 30-days preceding OP, n = 3
pathological risk factors. In line with published phase III study, \(^{14}\) CCRT was administered to patients with positive surgical margins and/or extranodal extension. Besides, patients having pN2 stage\(^{15}\) or presence of at least three minor risk factors\(^{16}\) also received CCRT. Minor risk factors included the following variables: pT4 or pN1 stage, close surgical margins (≤ 4 mm), poor differentiation (PD), perineural invasion (PNI), lymphatic invasion, vascular invasion, and tumor depth of invasion (DOI) >10 mm. Patients harboring two minor risk factors or pN1 at level IV–V were given postoperative RT alone. The radiation dose per fraction was 2 Gray (Gy)—with the total dose being 60–66 Gy for adjuvant postoperative RT and 66 Gy for CCRT.\(^{15}\) Dose escalation up to 70–72 Gy was allowed for patients who had evidence of early locoregional recurrence confirmed on biopsy or PET/CT imaging before adjuvant treatment. Cisplatin-based chemotherapy was used in the context of CCRT. All treatment decisions were taken by consensus within a multidisciplinary tumor board consisting of otolaryngologists, radiation oncologists, medical oncologists, radiologists, and pathologists. Posttreatment follow-up in the first 3 years consisted of medical visits performed every 3 months accompanied by imaging investigations (CT or MRI) every 3–6 months. Thereafter, visits were scheduled every 6 months and imaging studies on a yearly basis.

### 2.3 Calculation of SII and pathological risk factors

A preoperative CBC was retrospectively obtained from blood samples drawn in the 2 weeks preceding surgery for operative evaluation (median interval between blood sampling and operation: 5 days). SII was calculated by multiplying the absolute neutrophil and platelet counts, and then, divided by the absolute lymphocyte count. The following pathological risk factors were collected: surgical margins, extranodal extension (ENE), tumor depth of invasion, perineural invasion, lymphatic invasion, and vascular invasion. Patients were staged using the AJCC Staging Manual, Eighth Edition.

### 2.4 Data analysis

Categorical variables were analyzed by the chi-square test or the Fisher's exact test, as appropriate. Continuous data were compared using the independent Student's \(t\)-test (normally distributed variables) or the Mann–Whitney \(U\) test (skewed data). The frequency of missing data for pathological factors was <5% for all variables, the only exception being perineural invasion (7.6%). Because of the low missing data rate, multiple imputations were not required.\(^{17}\) The study endpoints—which included OS, local control (LC), regional control (RC), and distant control (DC)—were calculated from the first day of adjuvant RT/CCRT to the date of the event of interest (or censored on the date of last follow-up). Local control was defined as the absence of disease recurrence within the original tumor bed—to which a 2-cm margin was added. Regional control was diagnosed in the absence of regional lymph node (LN) recurrences. Distant control was defined by the absence of disease spread to distant LN or organs. Disease recurrence was diagnosed when recurrent lesions were identified on biopsy or using at least two different imaging modalities. Survival curves were plotted using the Kaplan–Meier method (log-rank test). Multivariable Cox proportional hazard regression analysis was used to identify independent risk factors for the outcomes of interest. The proportional hazards assumption was tested using graphical diagnostics based on the scaled Schoenfeld residuals and confirmed to be valid. All of the variables associated with the outcomes of interest at a level of \(p < 0.2\) in univariate analysis were entered into the multivariable model. The bootstrap method was used for internal validation. Results of multivariable analysis are expressed as adjusted hazard ratios (HRs) with their 95% confidence intervals (CIs). The optimal cutoff value for SII (810.6 in our study) was calculated with the Youden's index. All calculations were performed using the SPSS software package, version 20 (IBM). Two-tailed \(p\) values <0.05 were considered statistically significant. The presentation of this article follows the REMARK guidelines.\(^{18}\)

### 3 RESULTS

#### 3.1 Patient characteristics and treatment outcomes

The study sample consisted of 993 patients (92.8% men, median age: 51 years) with pathologically diagnosed OCSCC (Table 1). The three most common tumor sites were as follows: tongue (37.3%), buccal mucosa (34.1%), and gum (15.6%). Advanced T- or N- stages were identified in 87.8% and 46.8% of the study patients, respectively. Vascular invasion, lymphatic invasion, ENE, perineural invasion, and positive margins were identified in 4.9%, 6.4%, 34.7%, 51.3%, and 4.3% of patients, respectively. Adjuvant RT was given to all participants, and 58.8% of them received CCRT. The median dose used for RT was 66 Gy. The median duration of follow-up for patients who survived was 8.8 years. The 5-year and 10-year OS rates in the entire study cohort were 57.6% and 44.4%, respectively—with a median OS of 7.7 years (Figure 2A). The 5-year and 10-year LC, RC, and DC rates were 78.0%/75.5%, 85.1%/84.8%, and 80.6%/80.0%, respectively. The results of univariate
|                  | Entire cohort (N = 993) | Low SII (N = 646) | High SII (N = 347) | p       |
|------------------|-------------------------|-------------------|--------------------|---------|
| **Sex**          |                         |                   |                    |         |
| Men              | 922 (92.8%)             | 597 (92.4%)       | 325 (93.7%)        | 0.468   |
| Women            | 71 (7.2%)               | 49 (7.6%)         | 22 (6.3%)          |         |
| **Age**          |                         |                   |                    |         |
| <65 years        | 893 (89.9%)             | 577 (89.3%)       | 316 (91.1%)        | 0.383   |
| ≥65 years        | 100 (10.1%)             | 69 (10.7%)        | 31 (8.9%)          |         |
| **pT stage**     |                         |                   |                    | <0.001  |
| Stage 1−2        | 121 (12.2%)             | 102 (15.8%)       | 19 (5.5%)          |         |
| Stage 3−4        | 872 (87.8%)             | 544 (84.2%)       | 328 (94.5%)        |         |
| **pN stage**     |                         |                   |                    |         |
| Stage 0−1        | 528 (53.2%)             | 344 (53.3%)       | 184 (53.0%)        | 0.946   |
| Stage 2−3        | 465 (46.8%)             | 302 (46.7%)       | 163 (47.0%)        |         |
| **p Stage**      |                         |                   |                    | 0.009   |
| Stage 1−2        | 35 (3.5%)               | 30 (4.6%)         | 5 (1.4%)           |         |
| Stage 3−4        | 958 (96.5%)             | 616 (95.4%)       | 342 (98.6%)        |         |
| **Alcohol drinking** | 636 (64.0%)           | 408 (63.2%)       | 228 (65.7%)        | 0.425   |
| **Betel quid chewing** | 775 (78.0%)           | 494 (76.5%)       | 281 (81.0%)        | 0.102   |
| **Cigarette smoking** | 862 (86.8%)           | 528 (86.4%)       | 304 (87.6%)        | 0.585   |
| **Tumor site**   |                         |                   |                    |         |
| Tongue           | 370 (37.3%)             | 254 (39.3%)       | 116 (33.4%)        | 0.041   |
| Buccal mucosa    | 339 (34.1%)             | 200 (31.0%)       | 139 (40.1%)        |         |
| Gum              | 155 (15.6%)             | 100 (15.5%)       | 55 (15.9%)         |         |
| Retromolar       | 53 (5.3%)               | 37 (5.7%)         | 16 (4.6%)          |         |
| Mouth floor      | 37 (3.7%)               | 27 (4.2%)         | 10 (2.9%)          |         |
| Lip              | 20 (2.0%)               | 17 (2.6%)         | 3 (0.9%)           |         |
| Hard palate      | 19 (1.9%)               | 11 (1.7%)         | 8 (2.3%)           |         |
| **WHO differentiation** | 243 (24.5%)           | 142 (22.0%)       | 101 (29.1%)        | <0.001  |
| Well differentiated | 613 (61.7%)            | 427 (66.2%)       | 186 (53.8%)        |         |
| Moderately differentiated | 136 (13.7%)          | 76 (11.7%)        | 60 (17.3%)         |         |
| Poorly differentiated | 1 (0.1%)              | 1 (0.1%)          | —                  |         |
| Vascular invasion | 49 (4.9%)              | 33 (5.1%)         | 16 (4.6%)          | 0.679   |
| Lymphatic invasion | 64 (6.4%)              | 39 (6.0%)         | 25 (7.2%)          | 0.527   |
| Extranodal extension | 345 (34.7%)           | 222 (34.4%)       | 123 (35.4%)        | 0.733   |
| Margin positives | 43 (4.3%)               | 27 (4.2%)         | 16 (4.6%)          | 0.750   |
| Perineural invasion | 509 (51.3%)           | 322 (49.8%)       | 187 (53.9%)        | 0.744   |
| N/A              | 75 (7.6%)               | 61 (9.4%)         | 14 (4.0%)          |         |
| Depth of invasion >10 mm | 723 (72.8%)         | 428 (66.8%)       | 295 (85.3%)        | <0.001  |
| N/A              | 6 (0.6%)                | 5 (0.8%)          | 1 (0.3%)           |         |
| CCRT             | 584 (58.8%)             | 372 (57.6%)       | 212 (61.1%)        | 0.284   |
| Early recurrence before RT | 17 (1.7%)              | 4 (0.3%)          | 13 (3.7%)          | <0.001  |
| Surgery−RT interval >6 weeks | 299 (30.1%)          | 191 (29.6%)       | 108 (31.1%)        | 0.610   |

(Continues)
and multivariable analyses for the outcomes of interest are summarized in Tables 2 and 3.

### 3.2 Risk factors for poor local and regional control

The following unfavorable risk factors for LC were identified in univariate analysis: advanced N stage, alcohol drinking, betel quid chewing, treatment with CCRT, ENE, positive margins, and an interval between surgery and RT > 6 weeks. After allowance for potential confounders in multivariable analysis, alcohol drinking (adjusted HR = 1.394, \( p = 0.034 \); bootstrap validation, \( p = 0.027 \)), an interval between surgery and RT > 6 weeks (adjusted HR = 1.473, \( p = 0.008 \); bootstrap validation, \( p = 0.011 \)), positive margins (adjusted HR = 2.426, \( p = 0.001 \); bootstrap validation, \( p = 0.008 \)), and ENE (adjusted HR = 1.468, \( p = 0.010 \); bootstrap validation, \( p = 0.004 \)) were retained in the model as independent risk factors for LC. The following unfavorable risk factors for RC were identified in univariate analysis: advanced N stage, alcohol drinking, ENE, and treatment with CCRT. After allowance for potential confounders in multivariable analysis, alcohol drinking (adjusted HR = 1.639, \( p = 0.014 \); bootstrap validation, \( p = 0.010 \)) and ENE (adjusted HR = 2.508, \( p < 0.001 \); bootstrap validation, \( p = 0.001 \)) were retained in the model as independent risk factors for RC.

### 3.3 Distant control and predictive value of SII

Compared with patients with a low SII, those with high SII values had a higher disease burden (i.e., more advanced T stage as well as a higher frequency of poor differentiation, tumor depth of invasion > 10 mm, neoplasms of the buccal mucosa, and more early recurrence before adjuvant treatment; Table 1). High SII values were associated with poor DC. Compared with patients with low SII, those with high SII values had a higher 5-year DC rate (75.4% vs. 83.3%, respectively, \( p = 0.002 \)). Moreover, the median OS of patients with low SII was markedly higher than that of patients with high SII (9.4 years vs. 4.9 years, respectively, \( p < 0.001 \); Figure 2B). We then conducted a subgroup analysis in high-risk patients who received CCRT (median OS: 5.5 years). The results revealed that high SII scores were associated with less favorable OS figures even in this subgroup (3.4 years vs. 7.1 years, respectively, \( p = 0.002 \); Figure 2C). Similar findings were observed in patients with ENE—those are known to have a dismal prognosis (OS in patients with high vs. low SII scores: 1.2 years vs. 2.3 years, respectively, \( p = 0.003 \); Figure 2D). In multivariable analysis, higher SII values were independently associated with less favorable DC (adjusted HR = 1.683, \( p = 0.001 \); bootstrap validation, \( p = 0.003 \)) and OS (adjusted HR = 1.466, \( p < 0.001 \); bootstrap validation, \( p = 0.002 \)). Other significant predictors of OS identified in univariate analysis included advanced T/N stage, treatment with CCRT, alcohol drinking, an interval between surgery and RT > 6 weeks, total treatment time > 8 weeks, ENE, positive surgical margins, early recurrence before RT, perineural invasion, lymphatic invasion, and depth of tumor invasion > 10 mm. Besides SII, the following variables were retained in the multivariable model as independent risk factors for OS: alcohol drinking (adjusted HR = 1.308, \( p = 0.008 \); bootstrap validation, \( p = 0.011 \)), total treatment time > 8 weeks (adjusted HR = 1.616, \( p < 0.001 \); bootstrap validation, \( p = 0.001 \)), ENE (adjusted HR = 1.897, \( p < 0.001 \); bootstrap validation, \( p = 0.001 \)), positive surgical margins (adjusted HR = 2.558, \( p < 0.001 \); bootstrap validation, \( p = 0.002 \)), and lymphatic invasion (adjusted HR = 1.757, \( p = 0.001 \); bootstrap validation, \( p = 0.007 \)).

### 4 DISCUSSION

Owing to its capacity to improve LC, RC, and OS, postoperative RT is currently considered as the standard of care for patients with advanced OC-SCC. Moreover, an analysis of two randomized control trials demonstrated that CCRT improves LC, DFS, and OS in patients with positive surgical margins and ENE. Unfortunately, the clinical outcomes of patients with OC-SCC have remained stagnant over the last decade. Locoregional failure in areas receiving high radiation doses has been described as the most common pattern of disease recurrence following surgery and postoperative RT. However, the RTOG-7303 study indicated that distant metastases and secondary primary tumors are the predominant risk patients who received CCRT (median OS: 5.5 years).

### TABLE 1 (Continued)

| Risk factor                        | Entire cohort (N = 993) | Low SII (N = 646) | High SII (N = 347) | p    |
|------------------------------------|-------------------------|-------------------|--------------------|------|
| Total RT time >8 weeks             | 123 (12.4%)             | 77 (11.9%)        | 46 (13.3%)         | 0.542|
| Median RT dose (EQD2), Gy          | 66                      | 66                | 66                 | 0.079|
| Data are given as counts (percentages in parentheses), unless otherwise indicated. \( p \) values for differences between the high and low SII groups were calculated with the chi-square test. Statistically significant variables are marked in bold. Abbreviations: CCRT, concurrent chemoradiotherapy; N/A, not available, missing data; PET, positron emission tomography; RT, radiotherapy; SII, systemic immune-inflammation index; WHO, World Health Organization.
failure patterns after 2 years of follow-up in patients who underwent postoperative RT. Because of the clear prognostic relevance of distant failure, tools that may improve its risk stratification are eagerly awaited.

Inflammation and tumorigenesis are closely intertwined and several inflammatory markers may have prognostic significance in patients with malignancies. In this regard, the SII has been extensively investigated in patients with solid tumors—including esophageal cancer, hepatocellular carcinoma, urothelial carcinoma of bladder or upper urinary tract, cervical cancer, pancreatic cancer, and non-small cell lung cancer. Published studies consistently reported that SII independently predict OS, but data on its potential association with LC or distant metastases have been scanty. Moreover, the available literature is chiefly focused on patients treated with surgery, the only exception being a study conducted in non-small cell lung cancer—which also showed that high SII may predict a poor response to RT. A previous study found that SII is an independent prognostic factor for OS and disease-free survival in patients with oral cavity cancer. However, the authors did not focus on patients who underwent combination treatment and did not take other known risk factors into account.

The current study—in which all patients with OC-SCC received adjuvant RT or CCRT after surgery—demonstrated for the first time that high preoperative SII values are associated with a less favorable OS independent of potential confounders. Our data indicate that ENE was the strongest risk factors for adverse clinical outcomes. Notably, OS of patients with and without ENE was markedly different (1.75 years vs. 10.35 years, respectively). Nonetheless, patients with ENE and low SII had a more favorable OS compared with those with high SII values—suggesting that this index may be useful for risk stratification even in this high-risk subgroup. Similar findings were observed in the subset of patients who underwent CCRT. It is possible that such differences in terms of OS could be driven by a lower 5-year DC rate in patients with high SII values (75.4% vs. 83.3%). However, SII was not found to be associated with LC and RC—a finding which is in apparent

FIGURE 2 (A) overall survival in the entire study cohort (median: 7.7 years); (B) overall survival of patients with high versus low SII values (median: 4.9 years vs. 9.4 years, respectively, \( p < 0.001 \)); (C) overall survival of patients with high versus low SII values in the subgroup treated with chemoradiotherapy (median: 3.4 vs. 7.1 years, respectively, \( p = 0.002 \)); (D) overall survival of patients with high versus low SII values in the subgroup with extranodal extension (median: 1.2 vs. 2.3 years, respectively, \( p = 0.003 \))
| TABLE 2 | Univariate analysis of overall survival, local control, regional control, and distant control |
|-----------------|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| OS (HR, 95% CI) | LC (HR, 95% CI) | RC (HR, 95% CI) | DC (HR, 95% CI) |
| Age (≥65 vs. <65 years) | 1.263 (0.973–1.639) | 0.622 (0.355–1.092) | 0.884 (0.489–1.599) | 0.767 (0.444–1.323) |
| Sex (men vs. women) | 0.951 (0.689–1.312) | 0.839 (0.511–1.380) | 0.881 (0.475–1.631) | 1.018 (0.579–1.791) |
| pT stage (1−2 vs. 3−4) | 1.483 (1.114–1.974) | 1.496 (0.932–2.400) | 1.406 (0.794–2.491) | 1.545 (0.925–2.582) |
| pN stage (0−1 vs. 2−3) | 1.858 (1.567–2.203) | 1.467 (1.111–1.937) | 2.471 (1.737–3.515) | 3.525 (2.547–4.877) |
| CCRT | 1.505 (1.262–1.795) | 1.416 (1.061–1.888) | 1.724 (1.198–2.481) | 2.113 (1.521–2.934) |
| Alcohol drinking | 1.375 (1.143–1.654) | 1.421 (1.056–1.888) | 1.710 (1.164–2.511) | 1.299 (0.579–2.258) |
| Betel quid chewing | 1.117 (0.907–1.376) | 1.513 (1.041–2.197) | 1.995 (1.164–2.511) | 1.291 (0.885–1.883) |
| Cigarette smoking | 0.945 (0.738–1.209) | 1.056 (0.695–1.606) | 0.983 (0.598–1.613) | 1.360 (0.836–2.213) |
| Location (vs. tongue) | Buccal mucosa | 1.123 (0.907–1.441) | 1.178 (0.781–1.778) | 1.060 (0.706–1.596) | 0.920 (0.599–1.432) |
| | Gum | 1.020 (0.694–1.500) | 1.152 (0.624–2.128) | 0.512 (0.206–1.275) | 1.240 (0.510–2.930) |
| | Retromolar | 0.958 (0.598–1.536) | 0.267 (0.066–1.091) | 0.148 (0.021–1.067) | 0.990 (0.427–2.924) |
| | Mouth floor | 1.314 (0.749–2.305) | 1.311 (0.529–3.251) | 0.866 (0.272–2.760) | 1.253 (0.455–3.450) |
| | Lip | 1.550 (0.900–2.671) | 1.978 (0.858–4.558) | 0.633 (0.155–2.589) | 1.406 (0.510–3.872) |
| | Hard palate | 1.085 (0.885–1.330) | 1.181 (0.849–1.643) | 0.816 (0.559–1.192) | 1.404 (0.995–1.982) |
| | Differentiation MD versus WD | 1.271 (1.033–1.565) | 1.159 (0.834–1.610) | 0.379 | 1.730 (1.096–2.731) |
| | PD versus WD | 1.241 (0.925–1.665) | 0.822 (0.489–1.383) | 0.460 | 1.727 (0.949–3.145) |
| Surgery−RT interval >6 weeks | 1.336 (1.120–1.593) | 1.564 (1.176–2.080) | 0.978 (0.971–1.955) | 1.088 (0.793–1.492) |
| Total RT time >8 weeks | 1.876 (1.495–2.353) | 1.343 (0.889–2.030) | 1.548 (0.980–2.445) | 1.585 (1.064–2.359) |
| Positive margin | 1.959 (1.369–2.803) | 2.511 (1.505–4.188) | 1.731 (0.880–3.405) | 1.175 (0.578–2.388) |
| Extranodal extension | 2.068 (1.743–2.452) | 1.502 (1.127–2.003) | 2.441 (1.742–3.421) | 3.968 (2.933–5.369) |
| Early Recurrence before RT | 2.466 (1.421–4.281) | 2.186 (0.899–5.315) | 1.623 (0.517–5.099) | 2.276 (0.935–5.542) |
| Perineural invasion | 1.199 (1.003–1.432) | 1.028 (0.767–1.378) | 1.313 (0.919–1.877) | 1.807 (1.308–2.497) |
| Vascular invasion | 1.256 (0.864–1.827) | 0.788 (0.370–1.676) | 1.663 (0.873–3.168) | 1.693 (0.962–2.979) |
| Lymphatic invasion | 1.951 (1.437–2.650) | 1.798 (0.939–3.169) | 1.395 (0.732–2.659) | 2.522 (1.598–3.960) |
| Depth of invasion >10 mm | 1.431 (1.170–1.750) | 1.055 (0.773–1.439) | 1.171 (0.794–1.727) | 1.584 (1.099–2.282) |
| High SII | 1.417 (1.193–1.683) | 1.270 (0.954–1.690) | 0.984 (0.690–1.404) | 1.586 (1.182–2.128) |

Statistically significant variables are marked in bold. Abbreviations: CCRT, chemoradiotherapy; CI, confidence interval; DC, distant control; HR, hazard ratio; LC, local control; MD, moderately differentiated; OS, overall survival; PD, poorly differentiated; RC, regional control; RT, radiotherapy; SII, systemic immune-inflammation index; WD, well differentiated.
contrast with the previously reported association with high SII and radiation resistance. Nonetheless, comparisons should be interpreted cautiously because we used RT in an adjuvant setting, whereas it was given as primary treatment in the study by Tong et al. The goal of adjuvant radiotherapy is to clear microscopic disease foci—which elicit a less prominent inflammatory response compared to gross macroscopic tumors. This observation may offer an explanation for the lack of association between SII and LC/RC in our study. However, we found that SII was independently related with DC. Some mechanisms through which SII may be related to the occurrence of distant metastases are as follows: (1) neutrophil production of tumor necrosis factor (TNF)-α—a cytokine that impairs CD8+ T cells activity and induces vascular leaking, (2) platelet production of growth factors that protect malignant cells against natural killer cell-induced cell death, and (3) blunted lymphocyte-mediated immune response against malignant cells. Of interest, high SII values were related to depth of tumor invasion, advanced T stage, poor differentiation, anatomical location in the buccal mucosa, and early recurrence before RT. While some of these risk factors were associated to less favorable OS and DC figures, SII was the only factor retained in the multivariate model as an independent risk factor. Our findings may pave the way to further investigations on the clinical utility of preoperative SII to identify patients who could benefit from more aggressive treatment strategies. For example, the RTOG-0234 study demonstrated that concurrent treatment with docetaxel and cetuximab may reduce the risk of distant metastases compared with the scheme described in the RTOG-9501 (i.e., the standard treatment currently given to high-risk patients in our center). Metronomic adjuvant chemotherapy may also reduce distant recurrences. The utility of these approaches in patients with high preoperative SII values deserves further scrutiny.

Our findings need to be interpreted in the context of some limitations. Owing to the retrospective nature of the study, our investigation is prone to bias and needs independent confirmation in prospective cohorts. While our findings were internally validated using the bootstrap method, we did not conduct an external validation. Thus, the question as to whether our results are generalizable to different setting remains answered. We were unable to investigate the potential association between SII and treatment complications because of missing data related to adverse effects. Moreover, SII was determined on pretreatment blood samples without resorting to serial measurements. Further research is required to

| TABLE 3 | Multivariable analysis of overall survival, local control, regional control, and distant control |
|---------|--------------------------------------------------------------------------------------------------|
|          | Adjusted HR (95% CI) | p       | Bootstrap p |
| Overall survival |                                  |         |             |
| Alcohol drinking | 1.308 (1.072–1.595)    | 0.008  | 0.011       |
| Total RT time >8 weeks | 1.616 (1.265–2.065)    | <0.001 | 0.001       |
| Positive margin | 2.055 (1.416–2.981)    | <0.001 | 0.002       |
| Extranodal extension | 1.897 (1.582–2.274)    | <0.001 | 0.001       |
| Lymphatic invasion | 1.747 (1.276–2.392)    | 0.001  | 0.007       |
| High SII | 1.466 (1.225–1.755)    | <0.001 | 0.002       |
| Local control |                                  |         |             |
| Alcohol drinking | 1.394 (1.025–1.895)    | 0.034  | 0.027       |
| Surgery−RT interval >6 weeks | 1.473 (1.104–1.964)    | 0.008  | 0.011       |
| Extranodal extension | 1.468 (1.100–1.959)    | 0.009  | 0.004       |
| Positive margin | 2.426 (1.453–4.052)    | 0.001  | 0.008       |
| Regional control* |                                  |         |             |
| Alcohol drinking | 1.639 (1.105–2.432)    | 0.014  | 0.010       |
| Extranodal extension | 2.508 (1.764–3.565)    | <0.001 | 0.001       |
| Distant control |                                  |         |             |
| Extranodal extension | 3.416 (2.486–4.694)    | <0.001 | 0.001       |
| Perineural invasion | 1.494 (1.074–2.077)    | 0.017  | 0.019       |
| Lymphatic invasion | 1.911 (1.198–3.047)    | 0.007  | 0.007       |
| High SII | 1.683 (1.239–2.285)    | 0.001  | 0.003       |

Abbreviations: CI, confidence interval; HR, hazard ratio; RT, radiotherapy; SII, systemic immune-inflammation index.

*pN stage was not entered as a covariate into the multivariable model because of its high collinearity with extranodal extension (Pearson’s correlation =0.765, p < 0.001).
investigate whether SII may change during the course of RT or CCRT. We nonetheless believe that the value of pretreatment SII to identify high-risk patients with oral cavity cancer may be clinically relevant. Previous studies have shown that prolonged treatment duration can have an adverse impact on disease control.\textsuperscript{32,33} In this scenario, an appropriate treatment planning is critical to optimize outcomes. Subject to future validation in prospective studies, SII can be useful to guide treatment decisions. Finally, the optimal cutoff value for SII may vary across different populations.

In conclusion, the results of our study indicate that increased SII values are associated with poor clinical outcomes (OS and DC) in patients with OC-SCC treated with curative resection and adjuvant RT/CCRT. Owing to the higher risk of systemic failure in this patient group, a thorough follow-up surveillance schedule may be advisable; future research is required to examine this hypothesis more rigorously.

ACKNOWLEDGMENTS
The authors thank for the statistical assistance and acknowledge the support of the Maintenance Project of the Center for Big Data Analytics and Statistics (Grant CLRPG3D0047) at Chang Gung Memorial Hospital for statistical consultation and data analysis.

CONFLICT OF INTEREST
None.

FUNDING INFORMATION
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

DATA AVAILABILITY STATEMENT
The data sets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. Data cannot be made publicly available because of privacy regulations or ethical restrictions.

ORCID
Kai-Ping Chang https://orcid.org/0000-0003-1777-9578
Wen-Chi Chou https://orcid.org/0000-0002-0361-4548
Ching-Hsin Lee https://orcid.org/0000-0001-9861-2643
Yao-Yu Wu https://orcid.org/0000-0002-6491-7059
Yung-Chih Chou https://orcid.org/0000-0002-1723-2313
Joseph Tang-Chieh Chang https://orcid.org/0000-0003-4227-0546
Ngan-Ming Tsang https://orcid.org/0000-0002-2818-277X

REFERENCES
1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
2. Kano S, Homma A, Hatakeyama H, et al. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. Head Neck. 2017;39(2):247-253.
3. Rachidi S, Wallace K, Wrangle JM, Day TA, Alberg AJ, Li Z. Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1068-E1074.
4. Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D. Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: comparative analysis of inflammation-based prognostic scoring systems. Strahlenther Onkol. 2015;191(6):486-494.
5. Jonmrich G, Gruber ES, Winkler D, et al. Systemic Immune-Inflammation Index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–618.
6. Zhang Y, Lin S, Yang X, Wang R, Luo L. Prognostic value of pretreatment systemic immune-inflammation index in patients with gastrointestinal cancers. J Cell Physiol. 2019;234(5):5555-5563.
7. Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284.
8. Nie D, Gong H, Mao X, Li Z. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: a retrospective study. Gynecol Oncol. 2019;152(2):259-264.
9. Mirili C, Paydas S, Kapukaya TK, Yilmaz A. Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. Biomark Med. 2019;13(18):1565–1575.
10. Zhang W, Wang R, Ma W, et al. Systemic immune-inflammation index predicts prognosis of bladder cancer patients after radical cystectomy. Ann Transl Med. 2019;7(18):431.
11. Chovanec M, Cierza Z, Miskovska V, et al. Systemic immune-inflammation index in germ-cell tumours. Br J Cancer. 2018;118(6):831-838.
12. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-6222.
13. Dao P, Wu Y, Li J, et al. Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection. J Transl Med. 2018;16(1):365.
14. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952.
15. Lin CY, Fan KH, Lee LY, et al. Precision adjuvant therapy based on detailed pathologic risk factors for resected oral cavity squamous cell carcinoma: long-term outcome comparison of CGMH and NCCN guidelines. Int J Radiat Oncol Biol Phys. 2020;106(5):916-925.
16. Fan KH, Chen YC, Lin CY, et al. Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. Radiat Oncol. 2017;12(1):184.
17. Jakobsen JC, Gluud C, Weterslev J, Winke P. When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162.
18. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387-391.
19. Kramer S, Gelber RD, Snow JB, et al. Combined radiation therapy and surgery in the management of advanced head and neck cancer:
final report of study 73–03 of the Radiation Therapy Oncology Group. *Head Neck Surg*. 1987;10(1):19-30.

20. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). *Head Neck*. 2005;27(10):843-850.

21. Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. *J Clin Oncol*. 2015;33(29):3269-3276.

22. Yao M, Chang K, Funk GF, et al. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the University of Iowa experience. *Int J Radiat Oncol Biol Phys*. 2007;67(5):1332-1341.

23. Tupchong L, Scott CB, Blitzer PH, et al. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73–03. *Int J Radiat Oncol Biol Phys*. 1991;20(1):21-28.

24. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. *Nat Rev Cancer*. 2016;16(7):431-446.

25. Geng Y, Shao Y, Zhu D, et al. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. *Sci Rep*. 2016;6:39482.

26. Jan HC, Yang WH, Ou CH. Combination of the preoperative systemic immune-inflammation index and monocyte-lymphocyte ratio as a novel prognostic factor in patients with upper-tract urothelial carcinoma. *Ann Surg Oncol*. 2019;26(2):669-684.

27. Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. *J Transl Med*. 2017;15(1):221.

28. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. *Cancer Cell*. 2018;33(6):965-983.

29. Gajewski TF, Schreiber H, Fu XY. Innate and adaptive immune cells in the tumor microenvironment. *Nat Immunol*. 2013;14(10):1014-1022.

30. Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. *J Clin Oncol*. 2014;32(23):2486-2495.

31. Hsieh MY, Chen G, Chang DC, Chien SY, Chen MK. The impact of metronomic adjuvant chemotherapy in patients with advanced oral cancer. *Ann Surg Oncol*. 2018;25(7):2091-2097.

32. Kowalski LP, Carvalho AL. Influence of time delay and clinical upstaging in the prognosis of head and neck cancer. *Oral Oncol*. 2001;37(1):94-98.

33. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. *Int J Radiat Oncol Biol Phys*. 2003;57(3):693-700.

How to cite this article: Hung SP, Chen PR, Ho TY, et al. Prognostic significance of the preoperative systemic immune-inflammation index in patients with oral cavity squamous cell carcinoma treated with curative surgery and adjuvant therapy. *Cancer Med*. 2021;10:649–658. [https://doi.org/10.1002/cam4.3650](https://doi.org/10.1002/cam4.3650)